PharmAust (ASX:PAA) is conducting a Phase 2 trial for canines with B-cell lymphoma in Australia, New Zealand, and the USA.

So far, two dogs have had a partial response with a decrease in cancer tumour size, and another eight have had stable disease response.

One patient has surpassed 280 days with stable disease and a maintained quality of life.

The study aims to bridge the options of standard-of-care with chemotherapy and is expected to be completed by mid-2023.